EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Electrophysiological Effects of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor Dapagliflozin on Human Cardiac Potassium Channels

Mara Elena Müller iD, Finn Petersenn, Juline Hackbarth, Julia Pfeiffer, Heike Gampp, Norbert Frey, Patrick Lugenbiel, Dierk Thomas, Ann-Kathrin Rahm iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25115701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mara Elena Müller und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Glucosides, Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Xenopus laevis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heidelberg University, Joachim Siebeneicher Foundation, Department of Cardiology Heidelberg University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The sodium-glucose co-transporter-2 (SGLT2) inhibitor dapagliflozin is increasingly used in the treatment of diabetes and heart failure. Dapagliflozin has been associated with reduced incidence of atrial fibrillation (AF) in clinical trials. We hypothesized that the favorable antiarrhythmic outcome of dapagliflozin use may be caused in part by previously unrecognized effects on atrial repolarizing potassium (K+) channels. This study was designed to assess direct pharmacological effects of dapagliflozin on cloned ion channels Kv11.1, Kv1.5, Kv4.3, Kir2.1, K2P2.1, K2P3.1, and K2P17.1, contributing to IKur, Ito, IKr, IK1, and IK2P K+ currents. Human channels coded by KCNH2, KCNA5, KCND3, KCNJ2, KCNK2, KCNK3, and KCNK17 were heterologously expressed in Xenopus laevis oocytes, and currents were recorded using the voltage clamp technique. Dapagliflozin (100 µM) reduced Kv11.1 and Kv1.5 currents, whereas Kir2.1, K2P2.1, and K2P17.1 currents were enhanced. The drug did not significantly affect peak current amplitudes of Kv4.3 or K2P3.1 K+ channels. Biophysical characterization did not reveal significant effects of dapagliflozin on current–voltage relationships of study channels. In conclusion, dapagliflozin exhibits direct functional interactions with human atrial K+ channels underlying IKur, IKr, IK1, and IK2P currents. Substantial activation of K2P2.1 and K2P17.1 currents could contribute to the beneficial antiarrhythmic outcome associated with the drug. Indirect or chronic effects remain to be investigated in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsXenopus laevisHumansAnimalsPotassium ChannelsOocytesSodium-Glucose Transporter 2

Stichwörter der Autor:innen

K+ channelarrhythmiadapagliflozinion channelrepolarizationsodium-glucose co-transporter-2 (SGLT2) inhibitor

Substanzen

dapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsPotassium ChannelsSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
  • HCR (Heidelberg Center for Heart Rhythm Disorders), University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
  • DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg University, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.

ORCID-Profile: Mara Elena Müller, Ann-Kathrin Rahm

Förderung

  • Heidelberg University
  • Joachim Siebeneicher Foundation
  • Department of Cardiology Heidelberg University Hospital
  • German Heart Foundation
  • German Academic Scholarship Foundation
  • Heidelberg University, Faculty of Medicine
  • Cardiology Career Program of the Department of Cardiology

Zitieren

APA

Müller, M. E., Petersenn, F., Hackbarth, J., Pfeiffer, J., Gampp, H., Frey, N., Lugenbiel, P., Thomas, D., & Rahm, A. K. (2024). Electrophysiological Effects of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor Dapagliflozin on Human Cardiac Potassium Channels. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115701

Vancouver

Müller ME, Petersenn F, Hackbarth J, Pfeiffer J, Gampp H, Frey N, et al. Electrophysiological Effects of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor Dapagliflozin on Human Cardiac Potassium Channels. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115701

BibTeX
@article{Mller2024,
  author = {Müller, Mara Elena and Petersenn, Finn and Hackbarth, Juline and Pfeiffer, Julia and Gampp, Heike and Frey, Norbert and Lugenbiel, Patrick and Thomas, Dierk and Rahm, Ann-Kathrin},
  title = {Electrophysiological Effects of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor Dapagliflozin on Human Cardiac Potassium Channels},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25115701}
}
Kostenlos starten →